Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | E7386 |
| Synonyms | |
| Therapy Description |
E7386 inhibits the interaction between CBP and beta-catenin, resulting in decreased Wnt pathway signaling and potentially leading to alteration of the tumor microenvironment and decreased tumor growth (PMID: 33408116). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| E7386 | E 7386|E-7386 | WNT Inhibitor 17 | E7386 inhibits the interaction between CBP and beta-catenin, resulting in decreased Wnt pathway signaling and potentially leading to alteration of the tumor microenvironment and decreased tumor growth (PMID: 33408116). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| APC inact mut | desmoid tumor | predicted - sensitive | E7386 | Case Reports/Case Series | Actionable | In a Phase I trial, E7386 treatment demonstrated manageable safety and resulted in 2 partial responses in 55 patients with advanced solid tumors, including a partial response with treatment lasting 7.5 months in a patient with small bowel carcinoma and a partial response with treatment lasting 3.5 years in a patient with desmoid tumor (PMID: 41385966; NCT03833700). | 41385966 |
| APC inact mut | small intestine carcinoma | predicted - sensitive | E7386 | Case Reports/Case Series | Actionable | In a Phase I trial, E7386 treatment demonstrated manageable safety and resulted in 2 partial responses in 55 patients with advanced solid tumors, including a partial response with treatment lasting 7.5 months in a patient with small bowel carcinoma and a partial response with treatment lasting 3.5 years in a patient with desmoid tumor (PMID: 41385966; NCT03833700). | 41385966 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |